n-(3-cyano-4-methyl-1h-indol-7-yl)-3-cyanobenzene-sulfonamide and Thrombopenia

n-(3-cyano-4-methyl-1h-indol-7-yl)-3-cyanobenzene-sulfonamide has been researched along with Thrombopenia in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Giles, FJ; Hook, L; Kelly, KR; Krivelevich, I; Mita, A; Mita, M; Okereke, C; Ricart, AD; Romero, O; Rossignol, DP; Rowinsky, EK; Takimoto, C; Tolcher, A	1

Trials

1 trial(s) available for n-(3-cyano-4-methyl-1h-indol-7-yl)-3-cyanobenzene-sulfonamide and Thrombopenia

Article	Year
Phase I study of E7820, an oral inhibitor of integrin alpha-2 expression with antiangiogenic properties, in patients with advanced malignancies. Clinical cancer research : an official journal of the American Association for Cancer Research, 2011, Jan-01, Volume: 17, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Dose-Response Relationship, Drug; Female; Humans; Indoles; Integrin alpha2; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neoplasms; Neutropenia; Sulfonamides; Thrombocytopenia; Treatment Outcome	2011

Article

Year

Phase I study of E7820, an oral inhibitor of integrin alpha-2 expression with antiangiogenic properties, in patients with advanced malignancies.

Clinical cancer research : an official journal of the American Association for Cancer Research, 2011, Jan-01, Volume: 17, Issue:1

Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Dose-Response Relationship, Drug; Female; Humans; Indoles; Integrin alpha2; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neoplasms; Neutropenia; Sulfonamides; Thrombocytopenia; Treatment Outcome

2011